Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of LusiNEX and Tocilizumab in Healthy Volunteers
NCT03522012Phase 1Completed
- Sponsor
- Mycenax Biotech Inc.
- Start
- Oct 2017
- Primary completion
- Sep 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LusiNEX in rheumatoid arthritis (RA) (3 arms), sponsored by Mycenax Biotech Inc. Primary endpoint: Pharmacokinetics at 2 months. Started Oct 2017; status: completed.
02
Drugs
LusiNEX
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT03522012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03522012.